SCHEMBL18587828

SCHEMBL18587828

COCOc1ccccc1C#N

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.51
POLB P06746 1/20 0.51
ALDH1A1 P00352 4/20 0.51
TSHR P16473 2/20 0.51
HPGD P15428 1/20 0.51
NPC1 O15118 3/20 0.50
RAB9A P51151 3/20 0.50
SMN1; SMN2 Q16637 3/20 0.49
MAPK1 P28482 2/20 0.49
HTR1A P08908 1/20 0.47
ADRA2A P08913 1/20 0.47
ADRA2B P18089 1/20 0.47
MAOA P21397 1/20 0.47
HTR2B P41595 1/20 0.47
XDH P47989 1/20 0.46
KDM4E B2RXH2 1/20 0.44
TP53 P04637 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
THRB P10828 1/20 0.43
IMPDH2 P12268 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29530857 1.00 GAA (0.51) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL7466903 0.84 AR (0.46) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL21736886 0.84 SSTR4 (0.41) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL828475 0.83 AR (0.53) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL29530795 0.81 ALDH1A1 (0.51) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL1911338 0.81 ALDH1A1 (0.51) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL20607680 0.81 NPC1 (0.47) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL2291084 0.81 NPC1 (0.37) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL5451 0.80 SMN1; SMN2 (0.51) GAAPOLBALDH1A1TSHRHPGD
SCHEMBL30283197 0.80 SMN1; SMN2 (0.51) GAAPOLBALDH1A1TSHRHPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115557929-A Somatostatin modulators and uses thereof 克林提克斯医药股份有限公司 2023-01-03 CN claimed
CN-109715612-A SOMATOSTATIN MODULATORS AND USES THEREOF 克林提克斯医药股份有限公司 2019-05-03 CN claimed
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors CARDURION PHARMACEUTICALS, INC. (US) 2026-01-20 US disclosed
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2026-01-08 US disclosed
US-20240182474-A1 SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS CARDURION PHARMACEUTICALS, INC. 2024-06-06 US disclosed
US-11795172-B2 Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors CARDURION PHARMACEUTICALS, INC. (US) 2023-10-24 US disclosed
EP-4163276-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. (US) 2023-04-12 EP disclosed
CN-115557929-A Somatostatin modulators and uses thereof 克林提克斯医药股份有限公司 2023-01-03 CN disclosed
US-20220380337-A1 SOMATOSTATIN MODULATORS AND USES THEREOF Crinetics Pharmaceuticals, Inc. 2022-12-01 US disclosed
CN-109715612-B Somatostatin modulators and uses thereof 克林提克斯医药股份有限公司 2022-09-16 CN disclosed
EP-3484865-B1 SOMATOSTATIN MODULATORS AND USES THEREOF CRINETICS PHARMACEUTICALS INC (US) 2022-09-14 EP disclosed
US-11414397-B2 Somatostatin modulators and uses thereof Crinetics Pharmaceuticals, Inc. (US) 2022-08-16 US disclosed
US-20220098207-A1 FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS CARDURION PHARMACEUTICALS, INC. 2022-03-31 US disclosed
US-20210289794-A1 COMPOSITIONS AND RELATED METHODS FOR AGRICULTURE FLAGSHIP PIONEERING INNOVATIONS V, INC. 2021-09-23 US disclosed
CN-109715612-A SOMATOSTATIN MODULATORS AND USES THEREOF 克林提克斯医药股份有限公司 2019-05-03 CN disclosed
EP-3344619-A1 PHENOXYMETHYL DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-07-11 EP disclosed
WO-2017037146-A1 PHENOXYMETHYL DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2017-03-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12528816-B2 Substituted imidazo [1,2-b] pyridazines and [1, 2, 4] triazolo [ 4,3-b] pyridazines as camkii inhibitors RYR2, CACNA1C, CAMK4 GAA 3997/4885POLB 4240/4885ALDH1A1 1793/4885
US-11414397-B2 Somatostatin modulators and uses thereof SSTR5, SSTR2, SSTR4 GAA 198/4885POLB 4367/4885ALDH1A1 4626/4885
US-20220098207-A1 FUSED HETEROARYL COMPOUNDS AND THEIR USE AS CAMKII INHIBITORS CAMK2B, CAMK2A, CAMK2G GAA 3138/4885POLB 4219/4885ALDH1A1 2388/4885
US-20220380337-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR2, SSTR4 GAA 198/4885POLB 4367/4885ALDH1A1 4626/4885
US-20240182474-A1 SUBSTITUTED IMIDAZO [1,2-b] PYRIDAZINES AND [1, 2, 4] TRIAZOLO [ 4,3-b] PYRIDAZINES AS CAMKII INHIBITORS CAMK2B, RYR2, CAMK2A GAA 4467/4885POLB 3295/4885ALDH1A1 1868/4885
US-11795172-B2 Substituted imidazo[1,2-b]pyridazines and [1,2,4]triazolo[4,3-b]pyridazines as CaMKII inhibitors CAMK2B, RYR2, CAMK2A GAA 4467/4885POLB 3295/4885ALDH1A1 1868/4885
US-20260008767-A1 SOMATOSTATIN MODULATORS AND USES THEREOF SSTR5, SSTR3, SSTR2 GAA 2349/4885POLB 4734/4885ALDH1A1 4613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.